Search
Ethosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEthinylestradiol
go.drugbank.com/drugs/DB00977ApprovedInvestigational[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability. … [A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.
Mixtures: ACTIVA DE +TABLETAS RECUBIERTAS, ADELLA MINI TABLETA CON RECUBRIMIENTO DE GELATINACategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesClopenthixol
go.drugbank.com/drugs/DB13841InvestigationalIt is an antagonist at D1 and D2 dopamine receptors.
Relutrigine
go.drugbank.com/drugs/DB21614InvestigationalRelutrigine has a monoisotopic molecular weight of 407.08 Da. … Relutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).
Chlorthalidone
go.drugbank.com/drugs/DB00310ApprovedInvestigationalChlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. Chlorthalidone improves blood pressure and swelling by preventi...
Ivabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigational≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. … Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPimivalimab
go.drugbank.com/drugs/DB16667InvestigationalPimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After
Pixatimod
go.drugbank.com/drugs/DB19166InvestigationalPixatimod is under investigation in clinical trial NCT05061017 (Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide
Synonyms: Pg-545 free acidBasiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalA recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes
Paeonia lactiflora root
go.drugbank.com/drugs/DB16595InvestigationalMixtures: HAN SHIN GAMKONAL Extract Granules, HAN SHIN GAMKONAL Extract Granules